Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Comparing chemotherapy and surgery for rectal cancer after local resection

Official title: A Prospective, Multicenter, Randomized, Open, Parallel Controlled, Non-inferiority Clinical Trial of Salvage Chemoradiotherapy Versus Radical Total Mesorectal Excision in the Treatment of Intermediate-risk Early Middle-low Rectal Cancer After Local Resection

Run by Sun Yat-sen University · NCT06043999 · Data updated 2026-11-12

This study is testing whether chemotherapy or surgery works better for people with intermediate-risk rectal cancer who have already had part of their tumor removed.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment392 (estimated)
SponsorSun Yat-sen University
Academic / other
Drugs / interventionschemotherapy, radiation
Locations1 site (Guangzhou, Guangdong)
StatusRecruiting
StartedSeptember 1, 2023
Main results expectedDecember 31, 2028
Study endsDecember 31, 2028
Registry record updatedSeptember 21, 2023
Trial IDNCT06043999 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-75 with specific characteristics of T1 rectal adenocarcinoma who have undergone local radical resection.

Probably not a fit

Patients with other malignant tumors, inflammatory bowel disease, or those unsuitable for chemotherapy or surgery may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates whether salvage chemotherapy or total mesorectal excision (TME) is more effective for patients with intermediate-risk T1 rectal cancer who have undergone local resection. It aims to address the controversy surrounding the best treatment approach by comparing outcomes such as overall survival and disease-free survival between the two interventions. The study will include patients aged 18-75 who meet specific criteria related to tumor characteristics and health status. The goal is to determine the optimal treatment strategy that minimizes complications while effectively managing cancer recurrence.

Why it matters

Potential benefit: If successful, this study could provide a less invasive treatment option for rectal cancer patients, potentially improving their quality of life and reducing surgical complications.

How similar studies have gone: Previous studies have shown no significant difference in survival outcomes between salvage chemotherapy and TME, indicating that this approach is based on existing evidence but may still be novel in its specific application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. aged 18-75 years;
2. Local radical resection of rectal adenocarcinoma (TEM, TAMIS, TSPM, EMR, ESD or polypectomy)
3. pT1 with a diameter of 3-5 cm, or a maximum diameter of 3 cm, and at least poor differentiation and/or lymphovascular invasion and/or perineural invasion and/or SM3;
4. The distance from the lower edge of the tumor to the anal verge was within 10cm on MRI at initial diagnosis;
5. clinical stage N0M0 at initial diagnosis;
6. no multiple colorectal cancer;
7. The heart, lung, liver and kidney function can tolerate surgery;
8. Patients and their families were able to understand and willing to participate in this study, and provided written informed consent

Exclusion Criteria:

1. complicated with other malignant tumors or a previous history of malignant tumors;
2. not suitable for subsequent chemoradiotherapy or surgery;
3. a history of inflammatory bowl disease (IBD) or familial adenomatous polyposis (FAP);
4. recently diagnosed with other malignant tumors;
5. ASA physical status ≥ IV and/or ECOG performance status \> 2 points;
6. patients with severe liver and kidney function, cardiopulmonary function, coagulation dysfunction or combined with serious underlying diseases can not tolerate surgery;
7. a history of severe mental illness;
8. pregnant or lactating women;
9. Patients with other clinical or laboratory conditions were not considered to be eligible for the study

Where it's running

  • Gastrointestinal Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.